Scinai Immunotherapeutics (SCNI) Cost of Revenue (2024 - 2026)

Scinai Immunotherapeutics (SCNI) has 3 years of Cost of Revenue data on file, last reported at $1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 348.88% year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (changed N/A YoY), and the FY2025 full-year result was $6.7 million, up 443.05% from the prior year.
• Cost of Revenue fell to $1.6 million in Q1 2026, from $1.7 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $1.7 million in Q2 2025 to a low of $358000.0 in Q1 2025.
• A 3-year average of $888000.0 and a median of $417000.0 in 2024 frame the typical range for Cost of Revenue.
• Peak annual rise in Cost of Revenue reached 348.88% in 2026, while the deepest fall reached 348.88% in 2026.
• Tracing SCNI's Cost of Revenue over 3 years: stood at $373000.0 in 2024, then soared by 351.74% to $1.7 million in 2025, then dropped by 4.63% to $1.6 million in 2026.
• Business Quant data shows SCNI's Cost of Revenue at $1.6 million in Q1 2026, $1.7 million in Q2 2025, and $358000.0 in Q1 2025.